Author

C. Sachs

Institution: Novartis (Switzerland)

Observed institutions: Cedars-Sinai Medical Center, Novartis (Switzerland), Mayo Clinic, The University of Texas MD Anderson Cancer Center, Kyushu University, The Ohio State University Wexner Medical Center, Hospices Civils de Lyon, The Ohio State University

OpenAlex ID: A5111774456

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

2011 · M. H. Shah, C. Lombard-Bohas, et al. · Journal of Clinical Oncology · 21

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3).

2011 · M. H. Shah, T. Ito, et al. · Journal of Clinical Oncology · 21

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

2015 · J. Yao, N. Fazio, et al. · European Journal of Cancer · 10

Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study

2016 · James C. Yao, Nicola Fazio, et al. · 2

134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract

2015 · J.C. Yao, S. Singh, et al. · Annals of Oncology · 2

Pb1762 a Phase Iii, Randomized, Double‐blind Study of Intensive Induction and Consolidation Chemotherapy Plus Midostaurin (pkc412) or Placebo in Newly Diagnosed Patients With Flt3 Mutation Negative Aml

2019 · H. Döhner, F. Lo‐Coc, et al. · HemaSphere

Works count: 6

Citation count: 56

H-index: 3

I10-index: 3